Hot Products

Lucidin
Catalog No: CFN80213

Lucidin and its derivatives are genotoxic, it is mutagenic at the hypoxanthine-guanine phosphoribosyl transferase gene locus.

Lucidone
Catalog No: CFN98011

Lucidone possesses hepatoprotective, antioxidant and anti-inflammatory properties, it-mediated up-regulation of phase-II enzymes and HO-1 via Nrf-2 signaling pathway may provide a pivotal mechanism for its hepatoprotective action. Dietary intake of lucidone alleviates high fat diet-induced obesity in C57BL/6 mice and reveals the potential of lucidone as a nutraceutical to prevent obesity and consequent metabolic disorders. Lucidone accelerates wound healing through the cooperation of keratinocyte/fibroblast/ ndothelial cell growth and migration and macrophage inflammation via PI3K/AKT, Wnt/β-catenin and NF-κB signaling cascade activation. Lucidone also suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction, it could be a potential lead or supplement for the development of new anti-HCV agent in the future.

Lucidone B
Catalog No: CFN91025

Reference standards.

Lucidumol A
Catalog No: CFN95059

Lucidumol A has relatively good effect against aldose reductase with IC50 of 19.1uM. Lucidumol A has cytotoxic activity, it reduced cell growth in three human carcinoma cells (Caco-2, HepG2, and HeLa cells) dose dependently with LC50s from 20.87 to 84.36 uM.

Lucyoside B
Catalog No: CFN90905

Lucyoside B is a natural product from Luffa cylindrica ROEM.

Lumacaftor (VX-809)
Catalog No: CFN60062

VX-809 (Lumacaftor, VRT 826809) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells.

Lupalbigenin
Catalog No: CFN97245

Lupalbigenin sensitizes detachment-induced cell death in human lung cancer cell through down-regulation of pro-survival proteins.Lupalbigenin, laburnetin , and isolupalbigenin show promising cytotoxic effects toward HL-60 cells (IC50 4.3 ± 0.7 to 18.0 ± 1.7 uM).

Lupanine
Catalog No: CFN98924

Lupanine has a weak sedative effect on the central nervous system, interaction with specific drugs used for treatment of the CNS and for analgesic activity. Lupanine improves glucose homeostasis by influencing KATP-channels of pancreatic beta cells.

Lupenone
Catalog No: CFN99681

Lupenone and lupeol inhibit protein tyrosine phosphatase 1B (PTP1B) with IC50 values of 13.7 ± 2.1 and 5.6 ± 0.9 uM, respectively, they are non−competitive inhibitors of PTP1B, and PTP1B appears to be an attractive target for the development of new drugs for type 2 diabetes and obesity. Lupenone stimulates melanogenesis by increasing the tyrosinase enzyme expression via mitogen-activated protein kinase phosphorylated extracellular signal-regulated kinases 1 and 2 phosphorylation inhibition. A 1 : 4 mixture of Lupenone and caryophyllene oxide shows trypanocidal activity.

Lupeol
Catalog No: CFN98913

1. Lupeol has a potential to act as an anti-inflammatory, anti-microbial, anti-protozoal, anti-proliferative, anti-invasive, anti-angiogenic, antimalarial and cholesterol lowering agent.
2. Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade.
3. Lupeol and its ester derivative have beneficial effects on hypercholesterolemia-induced oxidative and inflammatory stresses.
4. Lupeol significantly enhances the radiosensitivity of SMMC-7721 cells in vitro and in vivo.
5. Lupeol shows antidiabetic and antioxidant potential in experimental hyperglycaemia.
6. Lupeol has potential anticancer effect against hepatocellular and pancreatic cancer, by inhibiting cell proliferation, inducing apoptosis and blocking Akt/PI3K and Wnt signaling pathway.
7. Lupeol has antiangiogenic effects, it (at 50 and 30 microg/mL) shows a marked inhibitory activity on human umbilical venous endothelial cells (HUVEC) tube formation while it does not affect the growth of tumor cell lines such as SK-MEL-2, A549, and B16-F10 melanoma.